公开(公告)号：US08198317B2

公开(公告)日：2012-06-12

申请号：US12536295

申请日：2009-08-05

Applicant: Sampath Parthasarathy ,  Sanjay Rajagopalan ,  Desikan Rajagopal

Inventor： Sampath Parthasarathy ,  Sanjay Rajagopalan ,  Desikan Rajagopal

IPC: A61K31/385 ,  C07D409/12

CPC classification number: A61K31/385 ,  A61K31/36 ,  A61K45/06 ,  C07D317/64 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.

Abstract translation: 本发明提供了新的亚甲二氧基酚类化合物及其衍生物，制备它们的方法以及使用它们治疗或预防心血管疾病，血管疾病和/或炎性疾病以及具有风险的I型和II型糖尿病和血脂异常患者的方法 用于高血压，中风，心血管和肾脏疾病。

公开(公告)号：US20100035849A1

公开(公告)日：2010-02-11

申请号：US12536295

申请日：2009-08-05

Applicant: Sampath Parthasarathy ,  Sanjay Rajagopalan ,  Desikan Rajagopal

Inventor： Sampath Parthasarathy ,  Sanjay Rajagopalan ,  Desikan Rajagopal

IPC: C07D317/48 ,  A61K31/496 ,  A61K31/47 ,  A61P9/00 ,  A61P29/00 ,  A61K31/497 ,  C07D409/14 ,  A61K31/385 ,  A61K31/36 ,  A61K31/415 ,  A61K31/60 ,  A61P1/00 ,  A61K31/40 ,  C07D409/02 ,  C07D405/14

CPC classification number: A61K31/385 ,  A61K31/36 ,  A61K45/06 ,  C07D317/64 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.

Abstract translation: 本发明提供了新的亚甲二氧基酚类化合物及其衍生物，制备它们的方法以及使用它们治疗或预防心血管疾病，血管疾病和/或炎性疾病的方法，以及患有风险的I型和II型糖尿病和血脂异常患者 用于高血压，中风，心血管和肾脏疾病。

公开(公告)号：US5773209A

公开(公告)日：1998-06-30

申请号：US484059

申请日：1995-06-07

Applicant: Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

Inventor： Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

IPC: G01N33/50 ,  A61K31/10 ,  A61K31/105 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/26 ,  A61K31/27 ,  A61K31/28 ,  A61K31/325 ,  A61K31/365 ,  A61K31/40 ,  A61K31/455 ,  A61K31/55 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61K49/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  C07D295/21 ,  G01N33/15 ,  G01N33/68 ,  G01N33/92 ,  G01N33/53

CPC classification number: C07D295/21 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/325 ,  A61K31/40 ,  A61K45/06 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  G01N33/68 ,  G01N33/92 ,  G01N2333/70503 ,  G01N2333/7056 ,  G01N2500/00 ,  G01N2800/323 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/861 ,  Y10S514/863 ,  Y10T436/201666

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

Abstract translation: 提供了一种治疗由VCAM-1介导的心血管疾病和非心血管炎性疾病的方法，其包括去除，降低浓度或预防氧化的多不饱和脂肪酸的形成，或干扰形成 多不饱和脂肪酸或氧化多不饱和脂肪酸和介导VCAM-1表达的蛋白质或肽。 还提供了抑制氧化还原敏感基因表达或激活通过氧化还原敏感途径抑制的基因的方法，其包括施用有效量的防止氧化信号氧化的物质，通常， 多不饱和脂肪酸的氧化，或干扰氧化信号与介导氧化还原基因表达的蛋白质或肽之间形成的复合物。

公开(公告)号：US5262439A

公开(公告)日：1993-11-16

申请号：US876557

申请日：1992-04-30

Applicant: Sampath Parthasarathy

Inventor： Sampath Parthasarathy

IPC: A61K31/215 ,  A61K31/10 ,  A61K31/22 ,  A61K31/222 ,  A61K31/225 ,  A61P3/06 ,  A61P9/10 ,  A61P31/12 ,  A61P39/06 ,  C07C319/20 ,  C07C323/20 ,  C07C67/08 ,  C07C69/017

CPC classification number: A61K31/225 ,  A61K31/10 ,  A61K31/22 ,  A61K31/222 ,  C07C323/20

Abstract: The invention provides a class of water-soluble probucol derivatives having one or more ester groups replacing the phenyl hydroxyl groups of the probucol molecule. Some derivatives have polar or charged functionalities such as carboxylic acid groups, amino groups, aldehyde groups and amide groups located on the ester groups. Some of these compounds are spontaneously hydrolyzable in typical biological milieus. The present invention also provides method of treating an animal with probucol by administering a water-soluble probucol prodrug to the animal.

Abstract translation: 本发明提供了一类具有一个或多个酯基的水溶性普罗布考衍生物，代替了普罗布考分子的苯基羟基。 一些衍生物具有极性或带电的官能团，例如位于酯基上的羧酸基团，氨基，醛基和酰胺基团。 这些化合物中的一些在典型的生物环境中是自发水解的。 本发明还提供了通过向动物施用水溶性普罗布考前药来治疗具有普罗布考的动物的方法。

公开(公告)号：US06589751B2

公开(公告)日：2003-07-08

申请号：US09184832

申请日：1998-11-02

Applicant: Eric Ferguson ,  Sampath Parthasarathy ,  Balaraman Kalyanaraman

Inventor： Eric Ferguson ,  Sampath Parthasarathy ,  Balaraman Kalyanaraman

IPC: G01N3353

CPC classification number: G01N33/6815 ,  Y10S435/81

Abstract: An antibody specific for homocystamide adducts is disclosed. In a preferred embodiment of the present invention, the antibody is used to evaluate the level of homocysteine in a biological sample.

Abstract translation: 公开了对高胱氨酰胺加合物特异性的抗体。 在本发明的优选实施方案中，所述抗体用于评价生物样品中同型半胱氨酸的水平。

公开(公告)号：US5846959A

公开(公告)日：1998-12-08

申请号：US471537

申请日：1995-06-06

Applicant: Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

Inventor： Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

IPC: G01N33/50 ,  A61K31/10 ,  A61K31/105 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/26 ,  A61K31/27 ,  A61K31/28 ,  A61K31/325 ,  A61K31/365 ,  A61K31/40 ,  A61K31/455 ,  A61K31/55 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61K49/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  C07D295/21 ,  G01N33/15 ,  G01N33/68 ,  G01N33/92 ,  A61K31/60 ,  A61K31/56 ,  A61K31/37

CPC classification number: C07D295/21 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/325 ,  A61K31/40 ,  A61K45/06 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  G01N33/68 ,  G01N33/92 ,  G01N2333/70503 ,  G01N2333/7056 ,  G01N2500/00 ,  G01N2800/323 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/861 ,  Y10S514/863 ,  Y10T436/201666

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

公开(公告)号：US5811449A

公开(公告)日：1998-09-22

申请号：US483335

申请日：1995-06-07

Applicant: Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

Inventor： Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

IPC: G01N33/50 ,  A61K31/10 ,  A61K31/105 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/26 ,  A61K31/27 ,  A61K31/28 ,  A61K31/325 ,  A61K31/365 ,  A61K31/40 ,  A61K31/455 ,  A61K31/55 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61K49/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  C07D295/21 ,  G01N33/15 ,  G01N33/68 ,  G01N33/92 ,  A61K31/54 ,  A61K31/265

CPC classification number: C07D295/21 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/325 ,  A61K31/40 ,  A61K45/06 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  G01N33/68 ,  G01N33/92 ,  G01N2333/70503 ,  G01N2333/7056 ,  G01N2500/00 ,  G01N2800/323 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/861 ,  Y10S514/863 ,  Y10T436/201666

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

公开(公告)号：US20130157986A1

公开(公告)日：2013-06-20

申请号：US13494606

申请日：2012-06-12

Applicant: SAMPATH PARTHASARATHY ,  SANJAY RAJAGOPALAN ,  DESIKAN RAJAGOPAL

Inventor： SAMPATH PARTHASARATHY ,  SANJAY RAJAGOPALAN ,  DESIKAN RAJAGOPAL

IPC: A61K31/385 ,  A61K45/06 ,  A61K31/36 ,  C07D409/12 ,  C07D317/64

CPC classification number: A61K31/385 ,  A61K31/36 ,  A61K45/06 ,  C07D317/64 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12

Abstract: Pharmaceutical compounds and compositions are provided which are methylenedioxy phenolic compounds and their derivatives, along with methods of making them and methods of using them for therapeutic purposes. The compounds and compositions are advantageous in that they can be used to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.

Abstract translation: 提供了药物化合物和组合物，其是亚甲二氧基酚类化合物及其衍生物，以及制备它们的方法和用于治疗目的的方法。 化合物和组合物的优点在于它们可用于治疗或预防心血管疾病，血管疾病和/或炎性疾病，以及患有高血压，中风，心血管和肾脏疾病风险的I型和II型糖尿病和血脂异常患者 。

公开(公告)号：US20100173936A1

公开(公告)日：2010-07-08

申请号：US12591560

申请日：2009-11-23

Applicant: Bobby V. Khan ,  Sampath Parthasarathy

Inventor： Bobby V. Khan ,  Sampath Parthasarathy

IPC: A61K31/47 ,  A61K31/385 ,  A61K31/20 ,  A61P3/00 ,  A61K31/40

CPC classification number: A61K31/385 ,  A61K31/435 ,  A61K2300/00

Abstract: Compositions are provided which can be useful in treating a renin-angiotensin aldosterone system-related disorder. These compositions include renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, as well as other therapeutic agents, and are useful in treating hypertension, stroke, metabolic syndrome, or other renin-angiotensin aldosterone system-related disorders in a subject. The compositions are also useful in improving vasodilation, reducing proteinuria, and reducing insulin resistance in a subject. Pharmaceutical compositions and methods of treatment using the compositions are further provided.

Abstract translation: 提供可用于治疗肾素 - 血管紧张素醛固酮系统相关疾病的组合物。 这些组合物包括肾素 - 血管紧张素醛固酮系统抑制剂和硫辛酸化合物以及其它治疗剂，并且可用于治疗受试者中的高血压，中风，代谢综合征或其他肾素 - 血管紧张素醛固酮系统相关疾病。 该组合物还可用于改善受试者的血管舒张，减少蛋白尿和降低胰岛素抵抗。 还提供了使用该组合物的药物组合物和治疗方法。

公开(公告)号：US5807884A

公开(公告)日：1998-09-15

申请号：US317399

申请日：1994-10-04

Applicant: Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

Inventor： Russell M. Medford ,  R. Wayne Alexander ,  Sampath Parthasarathy ,  Bobby V. Khan

IPC: G01N33/50 ,  A61K31/10 ,  A61K31/105 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/26 ,  A61K31/27 ,  A61K31/28 ,  A61K31/325 ,  A61K31/365 ,  A61K31/40 ,  A61K31/455 ,  A61K31/55 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61K49/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  C07D295/21 ,  G01N33/15 ,  G01N33/68 ,  G01N33/92 ,  A61K31/54 ,  A61K31/265

CPC classification number: C07D295/21 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/325 ,  A61K31/40 ,  A61K45/06 ,  C07C333/04 ,  C07C333/08 ,  C07C333/16 ,  G01N33/68 ,  G01N33/92 ,  G01N2333/70503 ,  G01N2333/7056 ,  G01N2500/00 ,  G01N2800/323 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/861 ,  Y10S514/863 ,  Y10T436/201666

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.